That's the initial consideration. After later reports from the parent company showed that sales for FY17 would be $US700 to $US750, the purchase agreement let Hikma renegotiate the cash upfront down by $US550m... from I think the initial agreement of $1.1B.
So final price for Roxanne was $2.1B, at operating margin of 35% like you quoted up there, that's EBIT of .35*700 = $US245m, or 8.6 P/EBIT.
Maybe paid practically $AUD1B [when you include the transaction, working capital, technical transfer] for a portfolio with FY17 sales of $US237m. EBITDA margin at 50% [they reckon] put earnings at $US118.5.
At current exchange rate, that's price of $US780m to $US118.5 or 6.58.
So it's cheaper on that PE measure. Here's the BUT...
Hikma's purchase only dilute its ownership b 16.7% compare to Mayne's issuing the equivalent of some 80% of existing shares.
Hikma immediately become the top 6 generic company vs Mayne's top 25.
Pipeline potentials of some US41b vs $US7b.
Get the labs, the R&D team and continued shared interests from the seller.
- Forums
- ASX - By Stock
- Fundamentals Are Strong
That's the initial consideration. After later reports from the...
Featured News
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.39 |
Change
-0.040(0.90%) |
Mkt cap ! $373.4M |
Open | High | Low | Value | Volume |
$4.44 | $4.48 | $4.22 | $618.1K | 142.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 693 | $4.33 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.40 | 2133 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 693 | 4.330 |
1 | 693 | 4.320 |
2 | 3793 | 4.310 |
2 | 1490 | 4.280 |
1 | 1085 | 4.220 |
Price($) | Vol. | No. |
---|---|---|
4.400 | 2133 | 2 |
4.410 | 693 | 1 |
4.440 | 1130 | 1 |
4.450 | 3649 | 3 |
4.470 | 1200 | 1 |
Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |